Small animal PET system for molecular imaging of rodents and primates

描述（由申请人提供）：申请资金用于购买最先进的西门子英威专用正电子发射断层扫描（DPET），用于我们在斯坦福大学继续进行的体内小型实验动物研究。该系统将安装在斯坦福大学体内成像创新中心（SCi3），该服务中心提供进行体内小动物成像研究的基础设施和专业知识。SCi3小动物成像资源支持许多个人以及多研究者计划的研究项目。能够在小型实验动物模型中研究疾病的高分辨率PET系统在对疾病动物模型成像方面发挥着重要和基础的作用，从而指导开发新的分子探针和检测方法，研究与疾病状态相关的基本分子过程，并帮助发现和监测新的基于分子的治疗方法的疗效。目前安装在SCi3服务中心的现有协和/西门子微型pet R4已广泛用于小鼠、大鼠和灵长类动物成像研究。然而，微型pet R4扫描仪，一个有10年历史的第一代小动物专用pet系统，性能过时，健康状况下降，已经超过了预期的使用寿命，零件和服务都不再可用。微型pet R4扫描仪的损坏将终止所有正在进行的nih资助的大鼠和小型灵长类动物研究。因此，我们选择了西门子Inveon DPET系统来取代现有的和过时的microPET R4。Inveon DPET系统将大大提高我们的PET性能，包括将体积分辨率提高四倍以上，并使我们能够研究大型啮齿动物（如老鼠、兔子）和小型灵长类动物（如松鼠猴），这些动物无法使用西门子Inveon多模态PET- ct扫描仪成像，该扫描仪也安装在SCi3服务中心。该系统将被放置在SCi3服务中心，用于支持当前和未来nih资助的研究，从研究癌症、心血管和神经疾病的分子基础到开发基于细胞的疗法。它还将用于评估斯坦福大学教师正在开发的一系列新诊断和治疗药物的药代动力学和疗效。与人类健康的相关性：在将新的诊断和治疗化合物应用于临床之前，需要进行临床前研究，在小鼠、大鼠和灵长类动物以及大型动物的适当模型中验证新的探针。该系统将为斯坦福国立卫生研究院资助的研究人员提供卓越的分子灵敏度、分辨率、视野和可靠性，以研究和开发下一代分子探针和分析，用于研究疾病的分子基础，并指导发现和监测新的基于分子的治疗方法。Inveon系统所提供的成功的探针、测定和治疗方法将被验证安全性和有效性，然后直接转化为临床，以改善人类疾病的管理。

DESCRIPTION (provided by applicant): Funding is requested to purchase a state-of-the-art Siemens Inveon dedicated positron emission tomography (DPET) for our continuing in vivo small laboratory animal research efforts at Stanford. The system will be installed in the Stanford Center for Innovations in In Vivo Imaging (SCi3), a service center that provides the infrastructure and expertise to conduct in vivo small animal imaging studies. The SCi3 small animal imaging resource supports many individual as well as multi-investigator program research projects. High resolution PET systems capable of studying disease in small laboratory animal models are playing an important and fundamental role to image suitable animal models of disease in order to guide the development of new molecular probes and assays that study the basic molecular processes associated with disease states in their natural environment within a living subject, and help to discover and monitor the efficacy of new molecular- based treatments. The existing Concorde/Siemens microPET R4 currently installed at the SCi3 service center has been extensively used for mouse, rat and primate imaging studies. However, the microPET R4 scanner, a 10 year-old, first generation small animal PET-only system with dated performance and declining health, has outlasted its projected use and both parts and service are no longer available for it. Breakage of the microPET R4 scanner would terminate all ongoing NIH-funded rat and small primate studies. Thus, the proposed Siemens Inveon DPET system was chosen to replace the existing and obsolete microPET R4. The Inveon DPET system will substantially advance our PET performance capabilities, including improving the volumetric resolution by over factor of four, as well as enabling us to study larger rodents (e.g., rats, rabbits) and small primates (e.g., squirrel monkeys), animals that cannot be imaged using the Siemens Inveon multimodality PET-CT scanner that is also installed in the SCi3 service center. The proposed system will be placed in the SCi3 service center and used to support current and future NIH-funded research ranging from studying the molecular basis of cancer, cardiovascular and neurological diseases to developing cellular-based therapies. It will also be used to evaluate the pharmacokinetics and efficacy of a range of new diagnostic and therapeutic agents under development by Stanford faculty. Relevance to human health: Prior to applying novel diagnostic and therapeutic compounds for clinical use, preclinical studies are required to validate new probes in appropriate models in mice, rats and primates, as well as larger animals. The proposed system will provide superior molecular sensitivity, resolution, field-of-view, and reliability for Stanford NIH-funded researchers to study and develop the next generation of molecular probes and assays designed for studying the molecular bases of disease, and guiding the discovery and monitoring of novel molecular-based treatment. The successful probes, assays, and treatments enabled by the proposed Inveon system will be validated for safety and efficacy and then directly translated to the clinic to improve the management of human diseases.